Voxilaprevir PK Fact Sheet

Details

Generic Name: Voxilaprevir
Trade Name: Vosevi® (co-formulated with sofosbuvir and velpatasvir)
Class: NS3 protease inhibitor
Molecular Weight: 868.9

Structure:

Summary of Key Pharmacokinetic Parameters

Linearity/non-linearity: AUC increases in a greater than dose-proportional manner over the dose range of 100 to 900 mg.
Steady state: Not reported.
Plasma half-life: ~33 h
Cmax: 192 ng/mL (in HCV infected patients).
Cmin: 5.7 (44.9) ng/mL (mean, %CV).
AUC: 2577 ng-hr/mL (in HCV infected patients).
Bioavailability: Not reported.
Absorption: AUC and Cmax increased by 112-435% and 147-680%, respectively, when voxilaprevir was taken with food.
Protein Binding: >99%
Volume of Distribution: Not reported.
CSF:Plasma ratio: Not reported.
Semen:Plasma ratio: Not reported.
Renal Clearance: Not excreted in urine.
Renal Impairment: No dose adjustment is required for patients with mild or moderate renal impairment. Safety data are limited patients with severe renal impairment or end-stage renal disease requiring haemodialysis. Vosevi can be used in these patients with no dose adjustment when no other treatment options are available.
**Voxilaprevir PK Fact Sheet**

**Hepatic Impairment**

No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh A).

Voxilaprevir is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C).

**Metabolism and Distribution**

- **Metabolised by**: CYP3A4
- **Inducer of**: None expected
- **Inhibitor of**: BCRP, OATP1B1/3, P-gp
- **Transported by**: BCRP, OATP1B1/3, P-gp

**References**

*Unless otherwise stated (see below), information is from:*

Vosevi Summary of Product Characteristics, Gilead Sciences Ltd.

Vosevi Prescribing Information, Gilead Sciences Inc.